These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1577978)

  • 41. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
    Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M
    Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of carcinoma cells in ascitic and pleural fluid. Comparison of four panepithelial antigens with carcinoembryonic antigen.
    Mezger J; Stötzer O; Schilli G; Bauer S; Wilmanns W
    Acta Cytol; 1992; 36(1):75-81. PubMed ID: 1546516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic value of clot examination for malignant cells in serous effusions.
    Jalal R; Aftab K; Hasan SH; Pervez S
    Cytopathology; 2009 Aug; 20(4):231-4. PubMed ID: 18627403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression.
    Mohamed F; Vincent N; Cottier M; Peoc'h M; Merrouche Y; Patouillard B; Paul S; Genin C
    Biomarkers; 2010 Jun; 15(4):315-24. PubMed ID: 20175704
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.
    Sadullahoglu C; Nart D; Veral A
    Diagn Cytopathol; 2017 Feb; 45(2):118-124. PubMed ID: 28024110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
    Marsan C; Gaulier A; Sabatier P; Garcia R
    Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
    Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
    Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic accuracy of epithelial membrane antigen for malignant effusions: a meta-analysis.
    Lin W; Liu X; Cen Y
    Int J Biol Markers; 2016 Feb; 31(1):e11-6. PubMed ID: 26743333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
    Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
    Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
    Ruitenbeek T; Gouw AS; Poppema S
    Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.
    Braunschweig T; Chung JY; Choi CH; Cho H; Chen QR; Xie R; Perry C; Khan J; Hewitt SM
    Diagn Pathol; 2015 May; 10():53. PubMed ID: 26022333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
    Liao ND; Lee WY
    Cancer Cytopathol; 2012 Aug; 120(4):269-75. PubMed ID: 22367930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of malignant effusions in body cavities].
    Hentrich M; Hartenstein R
    Internist (Berl); 1997 Aug; 38(8):794-804. PubMed ID: 9378629
    [No Abstract]   [Full Text] [Related]  

  • 55. Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.
    Lv M; Leng JH; Hao YY; Sun Y; Cha N; Wu GP
    Diagn Cytopathol; 2015 Jul; 43(7):527-31. PubMed ID: 25346242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions.
    Ensani F; Nematizadeh F; Irvanlou G
    Pol J Pathol; 2011; 62(2):95-100. PubMed ID: 21866465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions.
    Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J
    Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.
    Mullick SS; Green LK; Ramzy I; Brown RW; Smith D; Gondo MM; Cagle PT
    Acta Cytol; 1996; 40(5):855-60. PubMed ID: 8842156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid.
    Das DK; Al-Juwaiser A; George SS; Francis IM; Sathar SS; Sheikh ZA; Shaheen A; Pathan SK; Haji BE; George J; Kapila K
    Cytopathology; 2007 Jun; 18(3):157-67. PubMed ID: 17488258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.